Table 1.
Five-year follow-up of intravitreal bevacizumab (Avastin®) for inflammatory choroidal neovascularization
| Number/age (years)/gender/race | Disease | Duration at initial injection of Avastin (months) | OD1/OS2 | Initial vision as logMAR | Final vision as logMAR | Prior PO steroid therapy (0 = no, 1 = yes) | Prior subtenon steroid therapy | Prior intraocular steroid therapy (0 = no, 1 = injection, 2 = dexamethasone intravitreal implant) | Prior immunosuppressive therapy | Number of bevacizumab injections | Location of CNV membrane | Size of CNV (DD) | Uveitis at time of CNV (0 = inactive, 1 = active) | Initial foveal thickness (μ) | Final foveal thickness (μ) | Avastin dose (mL) | Complications |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1/26/F/C | TX | 0.5 | 2 | 0.7 | 0.4 | 0 | 0 | 0 | 0 | 1 | Subfoveal | 1.5 | 0 | NA | 170 | 0.05 | No |
| 2/30/M/A | TX | 24 | 2 | 0.48 | 0.3 | 1 | 0 | 0 | 0 | 1 | Subfoveal | 1.5 | 0 | 389 | 278 | 0.05 | No |
| 3/44/F/A | TB | 1 | 1 | 0.3 | 0 | 1 | 0 | 0 | 0 | 3 | Juxtafoveal | 1.5 | 0 | 282 | 140 | 0.05 | PSC |
| 4/51/F/C | PIC | 2 | 2 | 0.7 | 0.7 | 0 | 0 | 0 | 0 | 3 | Juxtafoveal | NA | 0 | NA | NA | 0.1 then 0.05 | No |
| 5/30/F/A | PIC | 1 | 1 | 0.9 | 0.1 | 0 | 0 | 0 | 0 | 3 | Subfoveal | 0.5 | 0 | NA | NA | 0.05 | No |
| 6/40/F/C | PIC | 4 | 1 | 0.0 | 0.0 | 1 | 0 | 1 | 0 | 13 | Juxtafoveal | 1 | 0 | 230 | 196 | 0.1 then 0.05 | No |
| 7/29/F/C | VKH | 12 | 1 | 1 | 0 | 1 | 1 | 2 | 1 | 15 | Juxtafoveal + peripapillary | 2 | 1 | 244 | 202# | 0.1 then 0.05 | No |
| 8/17/F/C | VKH | 96 | 1 | 0.54 | 0.1 | 1 | 1 | 0 | 1 | 1 | Juxtafoveal + peripapillary | 2 | 1 | 142* (NA) | 218** (NA) | 0.1 | PSC |
Notes:
Just after injection;
during an episode of uveitis;
different machines used at follow-up.
Abbreviations: A, Asian; C, Caucasian; CNV, choroidal neovascularization; DD, disc diameter; F, female; logMAR, logarithm of the minimum angle of resolution; M, male; NA, not assessable because of difference in optical coherence tomography machines between exams and/or value not available on the exact dates of initial treatment and 5 years after the first injection; OD, right eye; OS, left eye; PIC, punctate inner choroidopathy; PO, per os; PSC, posterior subcapsular cataract; TB, tuberculosis; TX, toxoplasmosis; VKH, Vogt–Koyanagi–Harada syndrome.